3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online

Toxicology Letters

Volumn 208, Issue 1, 2012, Pages 12-15

  Coppola, M ^a   Mondola, R ^b  

^a ASL CN2   (Italy)

^b ASL CN1   (Italy)

Author keywords

3,4 Methylenedioxypyrovalerone (MDPV); Bath salts; Designer drug; Synthetic cathinone

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; AMFEBUTAMONE; AMFEPRAMONE; CATHINONE; DESIGNER DRUG; NORPSEUDOEPHEDRINE; PYROVALERONE; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CHATA EDULIS; DELUSION; DEPRESSION; DRUG ABUSE; DRUG CONTROL; DRUG INTOXICATION; DRUG MARKETING; DRUG METABOLISM; FATIGUE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; LIPOPHILICITY; NEUROTOXICITY; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; SEIZURE; SHRUB; THORAX PAIN; TOBACCO DEPENDENCE;

ALKALOIDS; BENZODIOXOLES; DESIGNER DRUGS; DRUG AND NARCOTIC CONTROL; HUMANS; INTERNET; MARKETING; PSYCHOTROPIC DRUGS; PYRROLIDINES; STREET DRUGS; WORLD HEALTH;

EID: 80054872333     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.10.002     Document Type: Review

References (50)

1. Al-Habori M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin. Drug. Saf. 2005, 4:1145-1154.
2. Balint E.E., Falkay G., Balint G.A. Khat-a controversal plant. Wien. Klin. Wochenschr. 2009, 121:604-614.
3. Brenneisen R., Fisch H.V., Koelbing V., Geisshusler S., Kalix P. Amphetamine-like effect in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 1990, 30:825-828.
4. Brandt S.D., Freeman S., Summale H.R., Measham F., Cole J. Analysis of NRG "Legal highs" in the UK: identification and formation of novel cathinones. Drug Test. Anal. 2010, 2:377-382.
5. Centers For Disease Control and Prevention (CDC) Emergency department visits after use of a drug sold as "bath salts" -Michigan, November 13, 2010-March 31, 2011. MMWR Morb. Mortal. Wkly. Rep. 2011, 60:624-627.
6. Collins M. Some new psychoactive substances: precursor chemicals and synthesis-driven and -products. Drug Test. Anal. 2011, 3:404-416.
7. Colzato L.S., Ruiz M.J., Van den Wildenberg W.P.M., Hommel B. Khat use is associated with impaired working memory and cognitive flexibility. PLoS One 2011, 6:e20602.
8. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacob P., Ruoho A.E. Inhibition plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol. 1999, 381:63-69.
9. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal. 2011, 3:454-463.
10. Durham M. Ivory wave: the next mephedrone?. Emerg. Med. J. 2011, 10.1136/emj.2011.1129.20.
11. Gibbons S., Zloh M. An analysis of 'legal high' mephedrone. Bioorg. Med. Chem. Lett. 2010, 20:4135-4139.
12. Gordons G., Cole J.O. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr. Ther. Res.-Clin. Exp. 1971, 13:631-635.
13. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellison J.D., Allen S.C., et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 10.1124/jpet.111.184119.
14. Hassan N.A., Gunaid A.A., Murray-Lyon I.M. Khat (Catha edulis): health aspects of khat chewing. East Mediterr. Health J. 2007, 13:706-718.
15. (visited August 14, 2011). http://www.acep.org/Content.aspx%3Fid=77160.
16. (visited August 17, 2011). http://www.bluelight.ru/.
17. (visited September 29, 2011). http://www.caymanchem.com/pdfs/10624.pdf.
18. (visited August 15, 2011). http://www.drugguide.us/mdpv/encyclopedia.htm%23effects.
19. (visited September 29, 2011). http://www.drugrecognitionexpert.us/2011/02/bath-salts-mdpv/.
20. (visited August 17, 2011). http://www.drugs-forum.com/.
21. (visited August 11, 2011). http://www.emcdda.europa.eu/publications/drug-profiles/khat.
22. (visited August 11, 2011). http://www.emcdda.europa.eu/publication/drug-profiles/syntetic-cathinones.
23. (visited August 17, 2011). http://www.erowid.org/.
24. (visited August 14, 2011). http://www.iss.it/ssps/rili/cont.php%3Fid=2056%26lang=1%26tipo=2.
25. (visited August 14, 2011). http://www.namsdl.org/documents/ACMDCathinonesReport.pdf.
26. (visited August 13, 2011). http://pharmacycode.com/amphepramone.html.
27. (visited August 14, 2011). http://pharmacycode.com/bupropion.html.
28. (visited August 14, 2011). http://www.pubchem.ncbi.nlm.nih.gov/summary/summary.cgi%3Fcid=20111961.
29. (visited August 14, 2011). http://www.scribd.com/doc/57078733/Bath-Salt.
30. (visited August 16, 2011). http://www.sostanze.info/sites/default/files/documenti/Scheda_tecnica_MDPV.pdf.
31. (visited August 17, 2011). http://www.zoklet.net/.
32. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poison Information Service. Emerg. Med. J. 2010, 28:686-689.
33. Kalix P. The releasing effect of the alkaloid cathinone at centre and peripheral catecholamine storage sites. Neuropharmacology 1986, 25:499-501.
34. Kalix P. Chatinone, a natural amphetamine. Pharmacol. Toxicol. 1992, 70:77-86.
35. Kehr J., Ichinose F., Yoshitake S., Goiny M., Silvertsson T., Nyberg F., et al. Mephedrone compared to MDMA (ecstasy) and amphetamine rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, doi:10.111/j.1476-5381.2011.01499.x.
36. Meltzer P.C., Butler D., Deschamps R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49:1420-1432.
37. Meyer M.R., Maurer H.H. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 2010, 11:468-482.
38. Nencini P., Amiconi G., Befani O., Abdullahi M.A., Anania M.C. Possible involvement of amine oxidase inhibition in the sympathetic activation by khat (Catha edulis) chewing in humans. J. Ethnopharmacol. 1984, 11:78-86.
39. Ojanpera I.A., Heikman P.K., Rasanen I.J. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug. Monit. 2011, 33:257-263.
40. Penders T.M., Gestring R. Hallucinatory delirium following use of MDPV: "Bath Salts" Gen. Hosp. Psychiatry 2011, 10.1016/j.genhosppsych.2011.05.014.
41. Ross S., Peselow E. The neurobiology of addictive disorders. Clin. Neuropharmacol. 2009, 32:269-276.
42. Schifano F., Ricciardi A., Corazza O., Deluca P., Davey Z., Raffaelli C., et al. New drugs of abuse on the web: the role of the Psychonaut Web Mapping Project. Riv. Psichiatr. 2010, 45:88-93.
43. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214:593-602.
44. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with analytical confirmation "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin. Toxicol. 2011, 49:499-505.
45. Strano-rossi S., Cadwallader A.B., de la Torre X., Botrè F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 24:2706-2714.
46. Walsh C. Drugs, the internet and change. J. Psychoactive Drugs 2011, 43:55-63.
47. Westphal F., Junge T., Rosner P., Sonnichsen F., Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. Forensic Sci. Int. 2009, 190:1-8.
48. Winstock A.R., Mitcheson L.R., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
49. Wood D.M., Davies S., Greene S.L., Button J., Holt D.W., Ramsey J., et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin. Toxicol. 2010, 48:924-927.
50. Yohannan J.C., Bozenko J.S. The characterisation of 3,4-methylendioxypyrovalerone. Microgram J. 2010, 7:12-15.